Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Rolf W. Sparidans
Anti-Gd2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells
Pharmaceutical Research
Organic Chemistry
Biotechnology
Molecular Medicine
Pharmacology
Pharmaceutical Science
Related publications
412. Development of GD2-Specific Immunoliposomes for Immunotherapy of Neuroblastoma
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK
Scientific Reports
Multidisciplinary
Anti-Cd105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-Gd2 Antibody Immunotherapy of Neuroblastoma With Activated Natural Killer Cells
Clinical Cancer Research
Cancer Research
Oncology
Survivin Selective Inhibitor YM155 Promotes Cisplatin‑induced Apoptosis in Embryonal Rhabdomyosarcoma
International Journal of Oncology
Cancer Research
Oncology
Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines
Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Targeted Delivery of Paclitaxel to Tumor Cells: Synthesis and in Vitro Evaluation
Journal of Medicinal Chemistry
Drug Discovery
Molecular Medicine
Comparison of Pain Outcomes Between Two Anti-Gd2 Antibodies in Patients With Neuroblastoma
Pediatric Blood and Cancer
Oncology
Child Health
Hematology
Perinatology
Medicine
Pediatrics
Nanocarriers for Targeted Therapeutic Delivery to Cancer Cells
Science-Business eXchange
